임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
35건 표시
- 3상모집 중· Non-small Cell Lung Cancer (NSCLC)A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
리드: BMS · 협력: 바이오엔테크
- 3상모집 중· Non-Small Cell Lung Cancer (NSCLC)A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
리드: BMS · 협력: 바이오엔테크
- 3상모집 중· Breast NeoplasmsROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
리드: 바이오엔테크 · 협력: BMS
- 3상모집 중· Plaque PsoriasisLong-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
리드: BMS
- 3상모집 중· Bipolar Disorder Type I With ManiaA Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
리드: BMS
- 3상모집 중· Alzheimer's DiseaseA Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
리드: BMS
- 3상모집 중· Bipolar Disorder Type I With Mania or Mania With Mixed FeaturesA Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
리드: BMS
- 3상모집 중· Bipolar-I Disorder With Mania or Mania With Mixed FeaturesA Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
리드: BMS
- 3상모집 중· Multiple Sclerosis, Relapsing-RemittingStudy to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
리드: BMS
- 3상모집 중· Juvenile Psoriatic ArthritisA Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
리드: BMS
- 3상모집 중· Relapsed or Refractory Multiple Myeloma (RRMM)A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
리드: BMS
- 3상모집 중· Extensive-Stage Small Cell Lung CancerA Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
리드: BMS
- 3상모집 중· Extensive-stage Small-cell Lung CancerSafety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
리드: 바이오엔테크 · 협력: BMS
- 3상모집 중· Alzheimer DiseaseA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
협력: BMS
- 3상모집 중· Multiple MyelomaIberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
협력: BMS, 사노피
- 3상모집 중· Psychosis Associated With Alzheimer's DiseaseA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
협력: BMS
- 3상모집 중· Psychosis Associated With Alzheimer's DiseaseOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
협력: BMS
- 3상모집 중· Newly Diagnosed Multiple MyelomaNDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide
협력: BMS, 사노피
- 3상모집 중· Psychosis Associated With Alzheimer's DiseaseA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
협력: BMS
- 3상모집 중· Renal Allograft RecipientsA Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
리드: BMS
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.